登革热疫苗 z-bo 2020-09-16 467

　　The developer recently stated that the first dengue vaccine that can enter the market has shown promising results in clinical trials in Latin America, reducing the virus infection rate among veterans by 60.8%. The vaccine will be approved for use as early as next year, and countries affected by dengue fever will face a difficult decision: whether the limited protection provided by the vaccine is worth it.

　　Mosquito dengue fever is a climatic disease that spreads across tropical and subtropical regions and brings a heavy burden to medical care in Asian and American countries. It is estimated that due to the lack of effective drugs, 20,000 infected people die every year, and 500,000 patients require hospitalization. The first infection of one of the four different dengue virus serotypes is usually mild. The second serotype infection can cause severe symptoms, such as weak fever, joint and muscle pain, and internal bleeding.

　　Deng’s fever experts believe that delaying the complications of the second infection requires the vaccine to provide balanced protection against the four serotypes, and the development of vaccines is very high. It's hard for me. In an early study in Southeast Asia, more than 10,000 children and adolescents from five countries received 3 vaccinations. In addition to reducing the overall incidence of dengue fever, the vaccine also reduced severe cases by 88.5%. However, the effectiveness of the vaccine against serotype 2 was only 35%, which was the most popular serotype in the region at the time, so overall effectiveness was reduced. A Latin American trial recruited 20,875 participants in five countries/regions aged 9-16 years, which reduced the hospitalization rate by 80.3% and the efficacy of anti-type 2 serum was 42.3%. The results show that there are. Scientists from the leading pharmaceutical company Sanofi Pasteur will present details of the vaccine at the annual meeting of the American Society of Tropical Medicine and Health in November.

　　Sanofi Pasteur has invested 400 million US dollars to build a facility that can produce 100 million vaccines each year. The company announced that it will apply for vaccine approval in the second half of this year or early 2015. But in some countries, you don’t want to believe it. Singapore’s Environment Minister Vivian Barakrishnan previously stated that it is not enough to increase the national vaccination plan based on only the restrictions on vaccines for type 1 and type 2 sera shown in Southeast Asian trials.